{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Encorafenib+%26+Binimetinib+Treatment", "query": { "intervention": "Encorafenib & Binimetinib Treatment" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Encorafenib+%26+Binimetinib+Treatment&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-06T14:16:25.382Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03543969", "title": "Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Melanoma (Skin)", "Skin Cancer", "Skin Melanoma", "Skin Carcinoma" ], "interventions": [ { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2018-06-14", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-06T14:16:25.382Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03543969" }, { "nct_id": "NCT03915951", "title": "An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "encorafenib", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2019-06-04", "completion_date": "2025-10-03", "has_results": true, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-10-06T14:16:25.382Z", "location_count": 112, "location_summary": "Yuma, Arizona • Los Angeles, California • Santa Monica, California + 61 more", "locations": [ { "city": "Yuma", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03915951" }, { "nct_id": "NCT05260684", "title": "Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 716, "start_date": "2022-01-17", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2025-03-06", "last_synced_at": "2026-10-06T14:16:25.382Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05260684" }, { "nct_id": "NCT05097599", "title": "StrataPATH™ (Precision Indications for Approved Therapies)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Advanced Solid Tumor" ], "interventions": [ { "name": "lorlatinib", "type": "DRUG" }, { "name": "encorafenib + binimetinib", "type": "DRUG" }, { "name": "talazoparib", "type": "DRUG" }, { "name": "sacituzumab govitecan", "type": "DRUG" }, { "name": "axitinib", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki", "type": "DRUG" }, { "name": "enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Strata Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2022-04-29", "completion_date": "2024-06-12", "has_results": false, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-10-06T14:16:25.382Z", "location_count": 4, "location_summary": "St. Petersburg, Florida • Tallahassee, Florida • Kettering, Ohio + 1 more", "locations": [ { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "Kettering", "state": "Ohio" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05097599" }, { "nct_id": "NCT04655157", "title": "Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "encorafenib", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "ipilimumab", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jason J. Luke, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-05-28", "completion_date": "2022-09-20", "has_results": true, "last_update_posted_date": "2024-05-23", "last_synced_at": "2026-10-06T14:16:25.382Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04655157" }, { "nct_id": "NCT04741997", "title": "Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Melanoma Stage III", "Melanoma Stage IV", "BRAF V600 Mutation" ], "interventions": [ { "name": "Encorafenib Pill", "type": "DRUG" }, { "name": "Binimetinib Pill", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-05-24", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-06T14:16:25.382Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04741997" }, { "nct_id": "NCT03803553", "title": "Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colon Cancer", "Stage III Colon Cancer" ], "interventions": [ { "name": "FOLFIRI Protocol", "type": "DRUG" }, { "name": "ACTIVE SURVEILLANCE", "type": "OTHER" }, { "name": "Nivolumab Protocol", "type": "DRUG" }, { "name": "Encorafenib/Binimetinib/Cetuximab Protocol", "type": "DRUG" }, { "name": "Trastuzumab + Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2020-04-16", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-06T14:16:25.382Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03803553" }, { "nct_id": "NCT04044430", "title": "Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "Metastatic Microsatellite Stable Colorectal Carcinoma", "Metastatic Rectal Adenocarcinoma", "Stage III Colon Cancer", "Stage III Colorectal Cancer", "Stage III Rectal Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Colorectal Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Colorectal Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Colorectal Cancer", "Stage IIIC Rectal Cancer", "Stage IV Colon Cancer", "Stage IV Colorectal Cancer", "Stage IV Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Colorectal Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Colorectal Cancer", "Stage IVB Rectal Cancer", "Stage IVC Colon Cancer", "Stage IVC Colorectal Cancer", "Stage IVC Rectal Cancer" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-08-31", "completion_date": "2022-07-31", "has_results": false, "last_update_posted_date": "2023-01-09", "last_synced_at": "2026-10-06T14:16:25.382Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04044430" }, { "nct_id": "NCT04324112", "title": "Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hairy Cell Leukemia" ], "interventions": [ { "name": "binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2020-10-28", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-06T14:16:25.382Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04324112" }, { "nct_id": "NCT04800822", "title": "PF-07284892 in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "PF-07284892", "type": "DRUG" }, { "name": "lorlatinib", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "encorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2021-03-17", "completion_date": "2024-06-19", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-06T14:16:25.382Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Detroit, Michigan + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04800822" } ] }